Results 111 to 120 of about 7,007,196 (291)
Addiction, EarlyView.Abstract Background and aims Cocaine use disorder (CUD) is an increasingly widespread concern worldwide. Various pharmacological treatments have been investigated for CUD, but their efficacy remains unclear, and none have been licensed for treatment.
Craig Paterson +13 more
wiley +1 more source
Benzodiazepine receptors and the control of ingestive behaviour in the rat [PDF]
, 1996 When administered systemically, benzodiazepine receptor agonists have been shown to increase food intake in a number of species. Conversely, benzodiazepine receptor inverse agonists bring about reliable decreases in feeding.
Higgs, Suzanne, Higgs, S
core
Fentanyl exposure among patients seeking opioid treatment
, 2018 Aim: Overdoses attributed to the potent opioid agonist fentanyl have substantially increased in recent years. Despite these serious public health consequences, many opioid treatment providers do not currently include a fentanyl assay in their urine ...
Ochalek, T A +3 more
core +1 more source
Beyond abstinence: Redefining success in cannabis use disorder treatment
Addiction, EarlyView.Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin +3 more
wiley +1 more source
Opioid agonist treatment for pharmaceutical opioid dependent people (Review)
, 2016 Background There are increasing concerns regarding pharmaceutical opioid harms including overdose and dependence, with an associated increase in treatment demand.
Linda Gowing (20229114) +5 more
core +1 more source
Long-Acting Injectable naltrexone for the Management of patients with Opioid Dependence
Substance Abuse: Research and Treatment, 2011 Opioid dependence is a condition with serious clinical ramifications. Treatment has focused on detoxification, agonist therapy with methadone or buprenorphine, or remission maintenance with the opioid antagonist, naltrexone.
Kimberly L. Kjome, F. Gerard Moeller
doaj +1 more source
Addiction, EarlyView.Abstract Aims To investigate whether the treatment effect of extended‐release buprenorphine (BUP‐XR) on opioid‐free days in opioid use disorder (OUD) is mediated by reductions in opioid craving and improvements in personal functioning. Design and setting Exploratory causal mediation analysis using VanderWeele's four‐way decomposition framework in a 24 ...
John Marsden +11 more
wiley +1 more source
Interim opioid agonist treatment for opioid addiction
Opioid use disorder is a public health problem and treatment variability, coverage and accessibility poses some challenges. The study's objective is to review the impact of interim opioid agonist treatment (OAT), a short-term approach for patients awaiting standard OAT, in terms of treatment retention, access to standard OAT, quality of life and ...
Samsó Jofra, Laura|| +3 more
openaire +1 more source
Addiction, EarlyView.Abstract Background and aim Substance use disorders (SUDs) contribute significantly to global social and economic burden. Breathing‐based interventions offer a low‐cost, scalable adjunct or alternative to traditional treatment, yet their effects on substance use‐related outcomes has not been systematically evaluated.
Ariel Dart Roxburgh +7 more
wiley +1 more source
Informed Consent To Opioid Agonist Maintenance Treatment: Recommended Ethical Guidelines
, 2008 BACKGROUND: Some bioethicists have questioned whether opioid addicted individuals are able to provide free and informed consent to opioid agonist maintenance treatment. Conflicting motives for providing such treatment (e.g.
Hall, Wayne, Carter, Adrian
core +1 more source